Get the Stockscreener App
1.24
7.46%
-0.10
Pre-market:
1.26
0.02
+1.61%
Ocugen Inc stock is traded at $1.24, with a volume of 4.41M.
It is down -7.46% in the last 24 hours and down -22.50% over the past month.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
See More
Previous Close:
$1.34
Open:
$1.33
24h Volume:
4.41M
Relative Volume:
0.97
Market Cap:
$362.46M
Revenue:
-
Net Income/Loss:
$-63.08M
P/E Ratio:
-4.5926
EPS:
-0.27
Net Cash Flow:
$-72.53M
1W Performance:
-10.14%
1M Performance:
-22.50%
6M Performance:
+76.51%
1Y Performance:
+29.42%
1-Day Range:
$1.20
$1.33
1-Week Range:
$1.20
$1.42
52-Week Range:
$0.515
$1.90
Ocugen Inc Stock (OCGN) Company Profile
Name
Ocugen Inc
Sector
Industry
Phone
484-328-4701
Address
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.24 | 418.51M | 0 | -63.08M | -72.53M | -0.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.16B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
694.99 | 71.65B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.97 | 59.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
891.73 | 54.79B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
368.36 | 41.77B | 4.98B | 69.59M | 525.67M | 0.5197 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-24 | Initiated | Maxim Group | Buy |
| Mar-01-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-23-22 | Initiated | Mizuho | Buy |
| Jun-15-22 | Resumed | ROTH Capital | Buy |
| Jun-02-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-21 | Initiated | Noble Capital Markets | Outperform |
| Jun-11-21 | Downgrade | ROTH Capital | Buy → Neutral |
| May-07-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-09-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-04-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
View All
Ocugen Inc Stock (OCGN) Latest News
Key resistance and support levels for Ocugen Inc.July 2025 Chart Watch & Momentum Based Trading Ideas - newser.com
Is Ocugen Inc. stock resilient to inflationMarket Growth Summary & Fast Gain Swing Trade Alerts - newser.com
Price momentum metrics for Ocugen Inc. explainedWall Street Watch & Risk Managed Investment Signals - newser.com
How Ocugen Inc. (2H51) stock compares with tech leadersQuarterly Profit Review & Daily Oversold Bounce Ideas - newser.com
Combining price and volume data for Ocugen Inc.Quarterly Trade Report & Fast Moving Stock Watchlists - newser.com
Is Ocugen Inc. showing signs of accumulationWeekly Stock Summary & Consistent Profit Trade Alerts - newser.com
How high can Ocugen Inc. stock goJuly 2025 Macro Moves & Reliable Price Breakout Signals - newser.com
Is Ocugen Inc. still worth holding after the dipTrend Reversal & Weekly High Conviction Ideas - newser.com
Identifying reversal signals in Ocugen Inc.Weekly Stock Analysis & Community Verified Trade Signals - newser.com
Is Ocugen Inc. (2H51) stock a top dividend aristocrat candidateJuly 2025 Momentum & Free Expert Approved Momentum Trade Ideas - newser.com
Is Ocugen Inc. stock a safe investment in uncertain marketsWeekly Loss Report & Weekly High Return Forecasts - newser.com
Ocugen Advances Gene Therapy Pipeline as Phase 3 Trials Near Key Milestones - MyChesCo
Using economic indicators to assess Ocugen Inc. potentialPortfolio Return Summary & Low Risk Growth Stock Ideas - newser.com
Ocugen (OCGN) Is Down 7.0% After Mixed Q3 Results and Gene Therapy Milestones – What's Changed - simplywall.st
Ocugen (OCGN) Sees Higher Revenue but Wider Losses Is Funding the Pipeline a Growing Challenge? - Yahoo Finance
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on B - GuruFocus
How Ocugen Inc. (2H51) stock trades pre earningsRecession Risk & Real-Time Stock Price Movement Reports - newser.com
Will Ocugen Inc. stock outperform tech sector in 2025July 2025 Big Picture & Safe Entry Momentum Stock Tips - newser.com
Is it time to cut losses on Ocugen Inc.July 2025 Snapshot & Free Low Drawdown Momentum Trade Ideas - newser.com
Is Ocugen Inc. (2H51) stock resilient in recession scenariosSwing Trade & Risk Managed Investment Strategies - newser.com
Will Ocugen Inc. stock maintain dividend yieldFed Meeting & Target Return Focused Stock Picks - newser.com
Ocugen Reports Progress in Gene Therapy Trials Amid Financial Losses - MSN
Why Ocugen Inc. (2H51) stock trades below fair valueWeekly Gains Summary & Community Verified Swing Trade Signals - newser.com
Ocugen Inc (OCGN) Q3 2025 Earnings Call Highlights: Strategic Ad - GuruFocus
Ocugen Inc (OCGN) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Yahoo Finance
Is Ocugen Inc. stock ready for breakoutDay Trade & Real-Time Market Trend Scan - newser.com
Ocugen Inc Stock (OCGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.35%
0.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):